Triplet Combination First Line Treatment in Non Small Cell Lung Cancer (NSCLC)
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Phase I Study of CBP501 and Cisplatin in Patients With Advanced Refractory Solid Tumors
|4||Not yet recruiting||
CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors
† Study has passed its completion date and status has not been verified in more than two years.